JP2017515909A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017515909A5 JP2017515909A5 JP2017512461A JP2017512461A JP2017515909A5 JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5 JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017512461 A JP2017512461 A JP 2017512461A JP 2017515909 A5 JP2017515909 A5 JP 2017515909A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- seq
- concentration
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461994427P | 2014-05-16 | 2014-05-16 | |
| US61/994,427 | 2014-05-16 | ||
| US201462093734P | 2014-12-18 | 2014-12-18 | |
| US62/093,734 | 2014-12-18 | ||
| US201462095181P | 2014-12-22 | 2014-12-22 | |
| US62/095,181 | 2014-12-22 | ||
| PCT/IB2015/053602 WO2015173782A1 (en) | 2014-05-16 | 2015-05-15 | Antibody formulation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Division JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017515909A JP2017515909A (ja) | 2017-06-15 |
| JP2017515909A5 true JP2017515909A5 (cg-RX-API-DMAC7.html) | 2018-06-28 |
| JP6707528B2 JP6707528B2 (ja) | 2020-06-10 |
Family
ID=53200250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017512461A Active JP6707528B2 (ja) | 2014-05-16 | 2015-05-15 | 抗体処方物 |
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020035298A Active JP7277681B2 (ja) | 2014-05-16 | 2020-03-02 | 抗体処方物 |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US10556009B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3719038A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6707528B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102501602B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN106661111A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2015260758B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112016026811A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2949212C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3143047T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2927990T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL248802B (cg-RX-API-DMAC7.html) |
| MX (1) | MX381232B (cg-RX-API-DMAC7.html) |
| MY (1) | MY185802A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201609622PA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI694836B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2015173782A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| AU2015335743B2 (en) | 2014-10-23 | 2020-12-24 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| AU2017305856B2 (en) * | 2016-08-05 | 2024-09-12 | Csl Behring Gmbh | Pharmaceutical formulations of C1 esterase inhibitor |
| JP7377596B2 (ja) | 2017-02-22 | 2023-11-10 | アムジエン・インコーポレーテツド | 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法 |
| US10093731B2 (en) | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| KR20200014738A (ko) * | 2017-04-11 | 2020-02-11 | 키닉사 파마슈티컬스, 리미티드 | 안정한 항-osmr 항체 제형 |
| AU2018269656B2 (en) * | 2017-05-16 | 2024-07-11 | Octapharma Ag | C1-esterase inhibitor preparation |
| US11207412B2 (en) * | 2018-04-16 | 2021-12-28 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药（香港）有限公司 | 一种抗pd-l1抗体制剂 |
| EP3939611A4 (en) * | 2019-03-29 | 2022-12-21 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING ANTI-IL-5 ANTIBODY AND USE THEREOF |
| KR20220041881A (ko) * | 2019-07-29 | 2022-04-01 | 컴퓨젠 엘티디. | 항-pvrig 항체 제제 및 이의 용도 |
| CA3160207A1 (en) * | 2019-11-06 | 2021-05-14 | Novartis Ag | Treatment for sjogren's syndrome |
| GB202006093D0 (en) | 2020-04-24 | 2020-06-10 | King S College London | Composition |
| CN113546252A (zh) * | 2020-04-24 | 2021-10-26 | 上海君实生物医药科技股份有限公司 | 抗pcsk9抗体的药物递送装置 |
| US20230220092A1 (en) * | 2020-06-12 | 2023-07-13 | GlaxSmithKline Intellectual Property Management Limited | Anti-Blys Antibody for Treating Proteinuric Kidney Disease |
| CN116997359A (zh) | 2020-11-18 | 2023-11-03 | 阿斯利康(瑞典)有限公司 | 类固醇节制 |
| WO2022206872A1 (zh) | 2021-03-31 | 2022-10-06 | 江苏恒瑞医药股份有限公司 | 截短的taci多肽及其融合蛋白和用途 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| US20240254247A1 (en) * | 2021-06-17 | 2024-08-01 | Glaxosmithkline Intellectual Property Limited | Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC) |
| EP4377349A1 (en) | 2021-07-27 | 2024-06-05 | Astrazeneca AB | Treatment of lupus |
| WO2023226617A1 (zh) * | 2022-05-23 | 2023-11-30 | 南京融捷康生物科技有限公司 | 一种稳定的抗体制剂 |
| WO2024027793A1 (en) * | 2022-08-05 | 2024-02-08 | I-Mab Biopharma (Hangzhou) Co., Ltd. | Bispecific antibodies targeting ifnar1 and blys |
| TW202440636A (zh) | 2023-03-21 | 2024-10-16 | 美商傳記５５有限公司 | Ｃｄ１９／ｃｄ３８多特異性抗體 |
| CN118255895B (zh) * | 2024-04-30 | 2024-10-29 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 抗BAFF和hIL21双特异性抗体及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS57106673A (en) | 1980-12-24 | 1982-07-02 | Chugai Pharmaceut Co Ltd | Dibenzo(b,f)(1,4)oxazepin derivative |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| IL127127A0 (en) | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| ES2337986T3 (es) | 2001-08-10 | 2010-05-03 | Aberdeen University | Dominios de union de antigenos de peces. |
| AR035119A1 (es) * | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
| CA2466034C (en) * | 2001-11-08 | 2012-12-18 | Protein Design Labs, Inc. | Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| ES2379267T3 (es) | 2003-10-23 | 2012-04-24 | Novartis Vaccines And Diagnostics, Inc. | Composiciones estabilizadas |
| GT200600031A (es) * | 2005-01-28 | 2006-08-29 | Formulacion anticuerpo anti a beta | |
| EA015860B1 (ru) * | 2005-10-13 | 2011-12-30 | Хьюман Дженом Сайенсиз, Инк. | Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| RU2012153786A (ru) | 2010-05-28 | 2014-07-10 | Ново Нордиск А/С | Стабильные многодозовые композиции, содержащие антитело и консервант |
| JP2013530188A (ja) * | 2010-06-18 | 2013-07-25 | ヒューマン ゲノム サイエンシズ，インコーポレイテッド | 喘息並びに呼吸器系の他のアレルギー性及び炎症性症状を治療するためのｂリンパ球刺激タンパク質アンタゴニストの使用 |
| EP2648750B1 (en) * | 2010-12-10 | 2017-01-25 | Novartis AG | Antibody formulation |
| UY34105A (es) | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
| WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
| US20150239970A1 (en) | 2012-10-25 | 2015-08-27 | Medimmune, Llc | Stable, Low Viscosity Antibody Formulation |
| CA2898262A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
| TWI694836B (zh) | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
| US9762377B2 (en) | 2015-09-29 | 2017-09-12 | Cable Television Laboratories, Inc. | Hybrid full duplex communications in a radio frequency cable network |
-
2015
- 2015-05-14 TW TW104115341A patent/TWI694836B/zh active
- 2015-05-15 MY MYPI2016704190A patent/MY185802A/en unknown
- 2015-05-15 MX MX2016015006A patent/MX381232B/es unknown
- 2015-05-15 KR KR1020227036947A patent/KR102501602B1/ko active Active
- 2015-05-15 EP EP20150351.3A patent/EP3719038A1/en active Pending
- 2015-05-15 JP JP2017512461A patent/JP6707528B2/ja active Active
- 2015-05-15 SG SG11201609622PA patent/SG11201609622PA/en unknown
- 2015-05-15 DK DK15724070.6T patent/DK3143047T3/da active
- 2015-05-15 CN CN201580037513.2A patent/CN106661111A/zh active Pending
- 2015-05-15 EP EP19185861.2A patent/EP3715371A1/en not_active Withdrawn
- 2015-05-15 EP EP15724070.6A patent/EP3143047B8/en active Active
- 2015-05-15 AU AU2015260758A patent/AU2015260758B2/en not_active Ceased
- 2015-05-15 US US15/311,223 patent/US10556009B2/en active Active
- 2015-05-15 BR BR112016026811A patent/BR112016026811A2/pt not_active Application Discontinuation
- 2015-05-15 KR KR1020167034853A patent/KR20170005099A/ko not_active Ceased
- 2015-05-15 CA CA2949212A patent/CA2949212C/en active Active
- 2015-05-15 WO PCT/IB2015/053602 patent/WO2015173782A1/en not_active Ceased
- 2015-05-15 ES ES15724070T patent/ES2927990T3/es active Active
-
2016
- 2016-11-07 IL IL248802A patent/IL248802B/en active IP Right Grant
-
2018
- 2018-06-13 US US16/007,102 patent/US20180289804A1/en not_active Abandoned
-
2020
- 2020-01-07 US US16/736,042 patent/US11179463B2/en active Active
- 2020-03-02 JP JP2020035298A patent/JP7277681B2/ja active Active
-
2021
- 2021-11-05 US US17/519,606 patent/US12296007B2/en active Active
-
2025
- 2025-04-11 US US19/176,498 patent/US20250249095A1/en active Pending